Table 1

Demographic data, drug treatment, medical history, anti-dsDNA antibodies, SLAM scores, C3/C4 levels, and CR1 levels of all six patients with SLE

Patient	Sex/age/onset of disease	Current drug for treatment of SLE	Clinical manifestation*	Anti-dsDNA† (Farr titre, U/ml) ANA titre ENA profile	SLAM Day 0/day 28	C3/C4 (g/l) t = 0 h t = 4 h t = 24 h t = 48 h	CR1 on RBC
*Clinical manifestation may be acute or in the medical history; †baseline levels of anti-dsDNA antibodies before entering the study; ‡levels at screening visit (2 weeks before) were 0.82/0.19.
ENA, extractable nuclear antigen.
1	Female/55/1995	7.5 mg Prednisone	Arthritis	306	6/8	0.98/0.24‡	372
		400 mg Hydroxychloroquine	Livedo reticularis	1/ 1280		0.63/<0.06
		400 mg Hydroxychloroquine	Pleuritis	Negative		0.67/0.11
						0.82/0.11

2	Male/26/1984	5 mg Prednisone	Skin	45	2/1	0.57/0.11	106
		250 mg Chloroquine	Arthritis	1/80		0.49/0.08
		1000 mg Mycophenolatmofetil	Pleuritis	Negative		0.53/0.10
		1000 mg Mycophenolatmofetil	Renal			0.55/0.10
			Liver/ascites
			Leucopenia

3	Female/28/1993	125 mg Chloroquine	Raynaud’s syndrome	42	9/7	1.08/0.16	253
			Renal	1/320		0.95/0.17
			Skin vasculitis	U1RNP		0.1/0.15
			Leucopenia			1.04/0.17

4	Female/43/1980	5 mg Prednisone	Arthralgia	62	12/9	0.85/0.12	106
		50 mg Azathioprine	Myalgia	1/ 640		0.76/0.11
			Renal	SS-A, SS-B		0.78/0.11
			Raynaud’s syndrome			0.82/0.11

5	Male/30/2000	2.5 mg Prednisone	Renal	484	7/9	0.82/0.11	27
		400 mg Hydroxychloroquine	Pleuritis Arthritis	1/640 Negative		0.62/0.06 0.78/0.09
		Cyclophosphamide IV every 3 months	Endocarditis Leuco-lymphopenia			0.77/0.10
		2000 mg Mesalazine	Fever
			Colitis

6	Female/38/1999	10 mg Prednisone	Raynaud’s syndrome	27	9/6	0.83/0.14	54
		250 mg Chloroquine	Alopecia	1/640		0.77/0.13
			Livedo reticularis	Negative		0.77/0.13
			Arthralgia			0.82/0.15
			Photosensitive rash
			Neuroradiculitis